HDAC6 and cardiac hypertrophy: In conclusion, our study found that HDAC6 inhibition by TYA-018 reverses existing cardiac hypertrophy and diastolic dysfunction in multiple models of HFpEF, including the newly developed HFD+mTAC mouse model.